Sensitivity to bicalutamide, an oral AR inhibitor, was better in LAR cell lines than in other subtypes and a recent phase II study confirmed the interest of such drug showing a 19% of clinical benefit rate at 24 weeks for ER/PR-negative AR-positive breast cancer patients [5, 58]. This evidence concerns the gene ESR1 and breast carcinoma.